Research Topics
Species | Connie MarrasSummaryAffiliation: University Health Network Country: Canada Publications
| Collaborators
|
Detail Information
Publications
Protocol for a systematic review of prognosis after mild traumatic brain injury: an update of the WHO Collaborating Centre Task Force findingsCarol Cancelliere
Division of Health Care and Outcomes Research, Toronto Western Research Institute, University Health Network, Ontario, Canada
Syst Rev 1:17. 2012..Finally, we will identify gaps in the literature, and make recommendations for future research...- Fixing the broken system of genetic locus symbols: Parkinson disease and dystonia as examplesConnie Marras
Toronto Western Hospital Morton and Gloria Shulman Movement Disorders Centre and the Edmond J Safra Program in Parkinson s Disease, University of Toronto, Toronto, Canada
Neurology 78:1016-24. 2012.... 
Dihydropyridine calcium channel blockers and the progression of parkinsonismConnie Marras
Division of Neurology, Toronto Western Hospital, and University of Toronto, Toronto, Ontario, Canada
Ann Neurol 71:362-9. 2012..A study was undertaken to test the association between dihydropyridine calcium channel blocker use and the time to important milestones of disease progression among patients with parkinsonism...- Genetics meets environment: evaluating gene-environment interactions in neurologic diseasesConnie Marras
Toronto Western Hospital, University of Toronto, Ontario, Canada
Semin Neurol 31:553-61. 2011..Collaborations between genetics and environmental experts will be crucial to understand the complex relationships... - Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriersC Marras
Toronto Western Hospital, Edmond J Safra Program in Parkinson s Disease, Toronto, ON M5T 2S8 Canada
Neurology 77:325-33. 2011..Using a family study design, we describe the motor and nonmotor phenotype in probands with LRRK2 G2019S mutations and family members and compare these individuals to patients with idiopathic Parkinson disease (iPD) and unrelated controls... - Antipsychotics and mortality in ParkinsonismConnie Marras
Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, ON, Canada
Am J Geriatr Psychiatry 20:149-58. 2012..The use of antipsychotic medications is associated with an increased risk of death in older adults with dementia. The risk of death in patients with preexisting parkinsonism who receive antipsychotic drugs is not known... - Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohortsConnie Marras
Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, Toronto, Ontario, Canada
Mov Disord 26:608-13. 2011..We suspect that individuals employed full time may have a lower threshold for requiring dopaminergic therapy because of occupational demands... 
Antipsychotic use in older adults with Parkinson's diseaseConnie Marras
Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, University Health Network, Toronto, Canada
Mov Disord 22:319-23. 2007..Typical antipsychotics are still commonly being chosen as first-line agents for older patients, indicating a need for interventions to improve practice...- LRRK2 and Parkin mutations in a family with parkinsonism-Lack of genotype-phenotype correlationConnie Marras
Movement Disorders Centre, Toronto Western Hospital, Toronto, Canada
Neurobiol Aging 31:721-2. 2010..In the combined mutation carriers the age at onset and clinical course was highly variable and not always younger than in the carriers of LRRK2 G2019S mutations alone... - Pergolide associated cardiac valvulopathy based on Ontario administrative dataCindy Zadikoff
Morton and Gloria Shulman Movement Disorders Center, Toronto Western Hospital, Department of Neurology, Toronto, Ontario, Canada
Can J Neurol Sci 35:173-8. 2008.... - Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trialConnie Marras
Division of Neurology, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
Mov Disord 23:653-9; quiz 776. 2008..Our focus in clinical care needs to be broadened beyond assessing and treating Parkinsonism, recognizing the impact of mood, cognition and function on HRQOL... - New thyroxine treatment in older adults beginning lithium therapy: implications for clinical practiceKenneth I Shulman
Dept of Psychiatry and the Institute for Clinical Evaluative Sciences, Sunnybrook and Women s College Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada
Am J Geriatr Psychiatry 13:299-304. 2005.... - Atypical antipsychotics and parkinsonismPaula A Rochon
Institute for Clinical Evaluative Sciences, Kunin Lunenfeld Applied Research Unit, Baycrest Centre for Geriatric Care, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
Arch Intern Med 165:1882-8. 2005..This has not been well documented. We compared the risk of development of incident parkinsonism among older adults dispensed atypical relative to typical antipsychotics... - Confounders and intermediaries in case-control study designs: a strategy for distinguishing between the two when measured using the same variableAndrea Gruneir
Women s College Research Institute, Women s College Hospital, Toronto, Ontario, Canada
Pharmacoepidemiol Drug Saf 20:221-8. 2011.... - A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohortsConnie Marras
Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, Toronto, Ontario, Canada
Mov Disord 24:2370-8. 2009..This may relate to changes in philosophies with respect to starting treatment for Parkinson's disease, but the factors underlying this change remain to be elucidated... - The pill questionnaire in a nondemented Parkinson's disease populationWilliam Reginold
Toronto Western Hospital Movement Disorders Centre, and the Edmond J Safra Program in Parkinson s Disease, Toronto, Ontario, Canada
Mov Disord 27:1308-11. 2012..However, inaccurate medication reporting is associated with deficits spanning many cognitive domains and should alert a clinician to a higher likelihood of cognitive impairment... - Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort studySudeep S Gill
Institute for Clinical Evaluative Sciences, 2075 Bayview Avenue, Toronto, ON, Canada
BMJ 330:445. 2005..To compare the incidence of admissions to hospital for stroke among older adults with dementia receiving atypical or typical antipsychotics... - The curious case of phenocopies in families with genetic Parkinson's diseaseChristine Klein
Morton and Gloria Shulman Movement Disorders Center and the Edmond J Safra Program in Parkinson s Disease, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada
Mov Disord 26:1793-802. 2011.... - Management of neuropsychiatric symptoms in long-term care residents with Parkinson's disease: a retrospective cohort studyNathan Herrmann
Department of Psychiatry, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
Drugs Aging 30:19-22. 2013.... - Atypical antipsychotic use and parkinsonism in dementia: effects of drug, dose, and sexConnie Marras
Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, Toronto, Ontario, Canada
Am J Geriatr Pharmacother 10:381-9. 2012..There is a particular paucity of information on this in real-world use of these drugs, outside of clinical trial settings... - Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinicMargarita Pondal
Movement Disorders Centre, Toronto Western Hospital, University of Toronto, Canada
J Neurol Neurosurg Psychiatry 84:130-5. 2013.... - Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuationsConnie Marras
Division of Neurology, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
Mov Disord 19:22-8. 2004..We conclude that motor complications that occur within the first 4 years of treatment of PD do not have a significant negative effect on quality of life as measured by a visual analogue scale for most patients... - Invited article: changing concepts in Parkinson disease: moving beyond the decade of the brainConnie Marras
Toronto Western Hospital, University Health Network and University of Toronto, Ontario, Canada
Neurology 70:1996-2003. 2008..In this article, we highlight important changes in our understanding of PD in six general categories: definition, etiology, pathology, pathogenesis, clinical features, and therapeutics... - Unilateral versus bilateral tasks in early asymmetric Parkinson's disease: differential effects on bradykinesiaAsha Kishore
Division of Neurology, Department of Medicine, Toronto Western Hospital, Toronto, Ontario, Canada
Mov Disord 22:328-33. 2007..This observation also highlights the need to perform tasks of bradykinesia in one limb at a time for best accuracy... - Outcome measures for clinical trials in Parkinson's disease: achievements and shortcomingsConnie Marras
Toronto Western Hospital, Movement Disorders Centre, 7 McLaughlin, 399 Bathurst Street, Toronto, ON M5T 2S8, Canada
Expert Rev Neurother 4:985-93. 2004..Currently, neuroimaging techniques that reflect function of the dopaminergic system are the most promising biomarkers but still require additional validation... - Improvement of apathy after levofloxacin treatment: an N-of-1 studyMelissa Jo Armstrong
Department of Medicine Neurology, University of Toronto, Toronto, ON, Canada
Neurologist 18:146-8. 2012..We sought to determine whether this effect could be objectively supported and replicated outside the context of infection... - Predicting motor decline and disability in Parkinson disease: a systematic reviewConnie Marras
Morton and Gloria Shulman Movement Disorders Center, Toronto Western Hospital, University Health Network, University of Toronto, Ontario, Canada
Arch Neurol 59:1724-8. 2002..Greater baseline impairment, early cognitive disturbance, older age, and lack of tremor at onset appear to be adverse prognostic factors...